共 50 条
EASL Clinical Practice Guidelines on hepatitis E virus infection
被引:430
|作者:
Dalton H.R.
Kamar N.
Baylis S.A.
Moradpour D.
Wedemeyer H.
Negro F.
机构:
[1] EASL, EASL Bldg Home Hepatol,7 Rue Daubin, CH-1203 Geneva, Switzerland
关键词:
PEGYLATED INTERFERON-ALPHA;
CHRONIC LIVER-DISEASE;
NON-B HEPATITIS;
KIDNEY-TRANSPLANT;
RIBAVIRIN TREATMENT;
IGG SEROPREVALENCE;
BLOOD-DONORS;
NON-A;
EXTRAHEPATIC MANIFESTATIONS;
VIROLOGICAL RESPONSE;
D O I:
10.1016/j.jhep.2018.03.005
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Infection with hepatitis E virus (HEV) is a significant cause of morbidity and mortality, representing an important global health problem. Our understanding of HEV has changed completely over the past decade. Previously, HEV was thought to be limited to certain developing countries. We now know that HEV is endemic in most high-income countries and is largely a zoonotic infection. Given the paradigm shift in our understanding of zoonotic HEV and that locally acquired HEV is now the commonest cause of acute viral hepatitis in many European countries, the focus of these Clinical Practice Guidelines will be on HEV genotype 3 (and 4). (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1256 / 1271
页数:16
相关论文